Feasibility and early clinical impact of precision medicine for late-stage cancer patients in a regional public academic hospital.

Morten Ladekarl,Anne Krogh Nøhr,Mads Sønderkær, Simon Christian Dahl,Lone Sunde, Charles Vestereghem,Christophe Kamungu Mapendano,Charlotte Aaquist Haslund, Anja Pagh,Andreas Carus,Tamás Lörincz,Kinga Nowicka-Matus,Laurids Ø Poulsen,René Johannes Laursen,Karen Dybkær,Birgitte Klindt Poulsen,Jens Brøndum Frøkjær,Anja Høegh Brügmann,Anja Ernst,Alkwin Wanders,Martin Bøgsted,Inge Søkilde Pedersen

Acta oncologica (Stockholm, Sweden)（2023）

引用 1|浏览25

暂无评分

摘要

Precision medicine in end-stage cancer patients is feasible in a regional academic hospital but should continue within the frame of clinical protocols as few patients benefit. Close collaboration with comprehensive cancer centers ensures expert evaluations and equality in access to early clinical trials and modern treatment.

查看译文

关键词

Targeted treatment,cancer genomics,disparity,precision medicine,tumor board

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要